Objective: The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer. Methods: All the papers studied on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too. Results: (1) There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer who were candidates to analyze the efficacy. (2) The disease control rate and response rate in the whole group was 73.5% (95% CI: 65.5%-81.5%) and 29.1% (95% CI: 20.9%-37.3%), respectively; In first-line setting group they were 70.0% (95% CI: 55%-85%) and 41.7% (95% CI: 25.6%-57.8%), respectively; In non-first line setting group they were 71.6% (95% CI: 61.8%-81.4%) and 23.5% (95% CI: 14.3%-32.7%), respectively. The disease control rate between the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant (P = 0.045). (3) The incidence of acne-like rash was 72.0% (95% CI: 64.8%-79.2%), the degree I-II and degree III-IV account for 56.0% (95% CI: 48.1%-63.9%) and 16.0% (95% CI: 10.1%-21.9%), respectively. No treatment related death, and the hypersensitivity was under control. Conclusion: This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer. Objective: The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer. Methods: All the papers of on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too. Results: (1) There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer (2) The disease control rate and response rate in the whole group was 73.5% (95% CI: 65.5% - (95% CI: 20.9% -37.3%), respectively; In first-line setting group they were 70.0% (95% CI: 55% -85%) and 41.7% % -57.8%), respectively; In non-first line setting group they were 71.6% (95% CI: 61.8% -81.4%) and 23.5% (95% CI: 14.3% -32.7%), respectively. rate of the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant (P = 0.045). (3) The incidence of acne-like rash was 72.0% (95% CI: 64.8% -79.2%), the degree I-II and degree III-IV account for 56.0% (95% CI: 48.1% -63.9%) and 16.0% (95% CI: 10.1% -21.9%), respectively. death, and the hypersensitivity was under control. Conclusion: This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer.